homehealthcare News

SEC seeks more data for granting full market approval to Covishield, Covaxin: Sources

SEC seeks more data for granting full market approval to Covishield, Covaxin: Sources

SEC seeks more data for granting full market approval to Covishield, Covaxin: Sources
Profile image

By CNBCTV18.com Jan 14, 2022 11:06:01 PM IST (Updated)

SII had applied for market approval for the Covishield vaccine in December 2021 and Bharat Biotech has also applied for the same 10 days ago.

Drugs Controller General of India (DCGI)'s Subject Expert Committee on Friday sought more data from Bharat Biotech and Serum Institute of India (SII) before granting full market approval to Covaxin and Covishield, said sources.

Recommended Articles

View All

Sources added that SII and Bharat Biotech can't be allowed to sell Covaxin and Covishield in open market till government is mapping vaccination through specific nationwide drive via Cowin App.
SII had applied for market approval for the Covishield vaccine in December 2021 and Bharat Biotech has also applied for the same 10 days ago.
However, both Covaxin and Covishield are currently authorized for emergency use only. EUA does not represent approval of a vaccine in the full statutory term but authorises the use of an unapproved product or unapproved use of an approved product in a declared state of emergency such as a pandemic. A market authorisation label for a vaccine means it can be authorised for use without reservations or conditions.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!

Top Budget Opinions

    Most Read

    Market Movers

    View All
    Top GainersTop Losers
    CurrencyCommodities
    CompanyPriceChng%Chng